CytomX Therapeutics
CTMX
48 hedge funds and large institutions have $360M invested in CytomX Therapeutics in 2015 Q4 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$85.5M |
| 2 |
DM
Deerfield Management
New York
|
+$15M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.9M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$11.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$10.2M |
Top Sellers
CTMX Hedge Fund Activity: Q4 2015 in Review
48 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2015, worth a combined $360M.
Buyers outnumbered sellers: 48 funds opened new CTMX positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $85.5M.
- 48 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $360M of CytomX Therapeutics stock for Q4 2015.
- 48 funds opened new CytomX Therapeutics positions in Q4 2015 and 0 closed out, a net change of +48 holders.
- The largest CytomX Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $85.5M added.
Based on aggregated 13F filings for Q4 2015.